Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Broad-spectrum antibiotics target multiple gram-positive and gram-negative bacteria, and can collaterally damage the gut microbiota. Yet, our knowledge of the extent of damage, the antibiotic activity spectra, and the resistance mechanisms of gut microbes is sparse. This limits our ability to mitigate microbiome-facilitated spread of antibiotic resistance. In addition to antibiotics, non-antibiotic drugs affect the human microbiome, as shown by metagenomics as well as in vitro studies. Microbiome-drug interactions are bidirectional, as microbes can also modulate drugs. Chemical modifications of antibiotics mostly function as antimicrobial resistance mechanisms, while metabolism of non-antibiotics can also change the drugs' pharmacodynamic, pharmacokinetic, and toxic properties. Recent studies have started to unravel the extensive capacity of gut microbes to metabolize drugs, the mechanisms, and the relevance of such events for drug treatment. These findings raise the question whether and to which degree these reciprocal drug-microbiome interactions will differ across individuals, and how to take them into account in drug discovery and precision medicine. This review describes recent developments in the field and discusses future study areas that will benefit from systems biology approaches to better understand the mechanistic role of the human gut microbiota in drug actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 1×
“…overcome this limitation through differentiation of stem cells into specific intestinal cell types, such as enterocytes and goblet cells, forming crypt macrostructures, and encompass intestinal properties, such as barrier functions (Sato et al , 2009; Yin et al , 2014; Pearce et al , 2018).”
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“…of how the gut microbiome impacts anticancer immunotherapy by PD-1 (Tanoue et al , 2019), CTLA-4 blockage (V (cid:2) etizou et al , 2015; Sivan et al , 2015; Mager et al , 2020) or in cyclophosphamide therapy (Viaud et al , 2013), all resulting in findings of high transferability to…”
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life
Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., Li, Y., Xia, Y., Xie, H., Zhong, H., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.04.004 · Cited by 3,315
Environment dominates over host genetics in shaping human gut microbiota
Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D., Costea, P. I., Godneva, A., Kalka, I. N., Bar, N., et al. (2018) · Nature · doi:10.1038/nature25973 · Cited by 2,859 · cited 1×
“This composition is established in early stages of life (B € ackhed et al , 2015; Wampach et al , 2017) and is dependent more on the environment than on host genetics (Rothschild et al , 2018).”
Population-level analysis of gut microbiome variation
Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M. J., Valles-Colomer, M., Vandeputte, D., et al. (2016) · Science · doi:10.1126/science.aad3503 · Cited by 2,400 · cited 3×
“…disease, and how it changes over time, life stages, different geographic regions, and in response to environmental factors has increased dramatically over the last decade (The Integrative HMP (iHMP) Research Network Consortium, 2019; Pasolli et al , 2019; Nayfach et al , 2019; Falony et al , 2016).”
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Extensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905 · cited 2×
“Comparable to the described systematic bottom-up approach to test drug activity on representative panels of bacteria in isolation (Maier et al , 2018), similar efforts have been employed to deduce their metabolic activity against a large panel of drugs (Zimmermann et al , 2019b).”
Self-citationCox, L. M., Yamanishi, S., Sohn, J., Alekseyenko, A. V., Leung, J. M., Cho, I., Kim, S. G., Li, H., Gao, Z., Mahana, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.052 · Cited by 1,859 · cited 2×
“A number have examined the short-and long-term effects of antibiotics ( e.g ., Cox et al , 2014; Cho et al , 2012; Nobel et al , 2015; Ruiz et al , 2017).”
Cited by
Unravelling the collateral damage of antibiotics on gut bacteria
Maier, L., Goemans, C. V., Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Müller, P., Garcia-Santamarina, S., Cacace, E., Zhang, B., et al. (2021) · Nature · doi:10.1038/s41586-021-03986-2 · Cited by 391
Self-citationThe evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective
Valles-Colomer, M., Menni, C., Berry, S. E., Valdes, A. M., Spector, T. D., & Segata, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02260-4 · Cited by 114
Targeting the human gut microbiome with small-molecule inhibitors
Woo, A. Y. M., Aguilar Ramos, M. A., Narayan, R., Richards-Corke, K. C., Wang, M. L., Sandoval-Espinola, W. J., & Balskus, E. P. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00471-4 · Cited by 42
Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder
Trujillo-Del Río, C., Tortajada-Pérez, J., Gómez-Escribano, A. P., Casterá, F., Peiró, C., Millán, J. M., Herrero, M. J., & Vázquez-Manrique, R. P. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111670 · Cited by 19
Metadata
- Authors
- Zimmermann, M., Patil, K. R., Typas, A., & Maier, L.
- Venue
- Molecular Systems Biology
- Published
- 2021-03
- Volume
- 17
- Issue
- 3
- Pages
- e10116-e10116
- ISSN
- 1744-4292 (ISSN-L)
- OpenAlex
- W3138837064
- Cited by
- 121
- References
- 64
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Towards a mechanistic understanding of reciprocal drug–microbiome interactions. https://app.cochat.ai/papers/10.15252/msb.202010116
- The paper
- Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021). Towards a mechanistic understanding of reciprocal drug–microbiome interactions. Molecular Systems Biology. https://doi.org/10.15252/msb.202010116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.